Skip to main content
. Author manuscript; available in PMC: 2024 Jul 1.
Published in final edited form as: Am J Hematol. 2023 May 19;98(7):1029–1042. doi: 10.1002/ajh.26935

Figure 5. Regulation of hepcidin by JAK inhibitors.

Figure 5.

A) Schematic of hepcidin regulation.

B) Hepcidin (HAMP) mRNA expression across multiple cell line lineages from the Cancer Cell Line Encyclopedia.

C) qRT-PCR of HAMP expression upon JAK treatment in the presence of BMP6 stimulation in HepG2 cells. Cells were treated with 0.5 μM JAK inhibitor and/or 10ng/mL BMP6 for 24 hours. N = 3 replicates. HAMP expression normalized to actin (ACTB).

D) Immunoblot of JAK-STAT, SMAD, and S6 signaling pathways upon JAK inhibitor treatment in the presence of BMP6 stimulation. Cells were treated with 1 μM JAK inhibitor and/or 10ng/mL BMP6 for 24 hours.

E) qRT-PCR of HAMP expression upon JAK treatment in the presence of IL-6 stimulation in HepG2 cells. Cells were treated with 1 μM JAK inhibitor and/or 10ng/mL IL-6 for 24 hours. N = 3 replicates. HAMP expression normalized to actin (ACTB).

F) Immunoblot of the JAK-STAT pathway upon JAK inhibitor treatment in the presence of IL-6 stimulation. Cells were treated with 1 μM JAK inhibitor and/or 10ng/mL IL-6 for 24 hours.